The non-exclusive agreement provides Merck Millipore the opportunity to continue to develop and ultimately commercialize iPS cells for research applications. Under the agreement, Merck Millipore will continue to offer its STEMCCA™ reprogramming kits, which provide a highly efficient, reproducible method for creating iPS cells.

Merck Millipore press release, September 17, 2012